Business Context and Reporting Period
Company: IRIDEX CORPORATION
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2006
Subject: Non-reliance on previously issued financial statements for the first quarter of fiscal year 2006 (ended April 1, 2006) due to revenue recognition errors.
Key Financial Metrics and Restatement Impact
The filing details a restatement of the Q1 2006 financials. The adjustments resulted in the following changes:
- Total Revenue: Decreased from $9.0 million to $8.8 million.
- Net Loss: Increased from $264,000 to $303,000.
- Net Loss Per Share (Basic and Diluted): Increased from ($0.03) to ($0.04).
- Cash Flow: No impact on operating, investing, or financing cash flows.
Specific Adjustments Identified:
- Revenue reduction of $101,000 due to non-standard return rights (associated cost of sales reduction: $64,000; operating expense reduction: $6,000).
- Revenue reduction of $48,000 due to failure to defer revenue where title transfer did not occur (associated cost of sales reduction: $20,000; operating expense reduction: $3,000).
- Revenue reduction of $18,000 due to failure to defer revenue for undelivered elements in multi-element arrangements.
- Income tax benefit and accruals increased by $35,000.
Material Changes and Investigation Findings
An independent review initiated in August 2006 following an allegation of premature revenue recognition in Q4 2004 concluded that while the specific allegation was valid, it did not stem from wrongful intent. The review uncovered additional errors from Q4 2003 through Q1 2006.
- Materiality: Errors in periods from Q4 2003 through December 31, 2005, were deemed immaterial to previously issued statements. However, the Q1 2006 errors required restatement.
- Segments Affected: Ophthalmology and Dermatology segments.
- Control Deficiencies: Management identified a material weakness in internal controls regarding the completeness and accuracy of the revenue recognition process.
Outlook, Risks, and Management Commentary
Management Action: The Audit Committee determined that the Q1 2006 Form 10-Q should no longer be relied upon. An amended Form 10-Q/A will be filed to reflect the restated financials.
Risks and Contingencies:
- Internal Controls: The company acknowledged a material weakness in internal controls that could result in material misstatements not prevented or detected.
- Accounting Firm: The decision to restate and the disclosed matters have been discussed with PricewaterhouseCoopers LLP, the independent registered public accounting firm.
Investor Verification Checklist
- Verify the filing of the amended Form 10-Q/A for the quarter ended April 1, 2006.
- Review the updated internal control assessment and remediation plans for revenue recognition processes.
- Confirm that the restatement adjustments align with the specific dollar amounts disclosed ($81,000 revenue reduction total).
- Monitor for any further disclosures regarding the independent review of periods prior to Q1 2006.